Johnson & Johnson's Strategic Acquisition Bolsters its Immunology Pipeline

2024-05-20

并购临床3期临床结果免疫疗法生物类似药

Johnson & Johnson has made another strategic move in the pharmaceutical industry by acquiring Proteologix, a biopharmaceutical company focused on developing bispecific antibodies for the treatment of immune-mediated diseases. The $850 million cash deal, which is expected to close in mid-2024, will further strengthen Johnson & Johnson's immunology portfolio.

Proteologix's pipeline includes two lead candidates, PX128 and PX130, both bispecific antibodies targeting different pathways involved in the pathogenesis of moderate-to-severe atopic dermatitis (AD) and asthma. By simultaneously modulating multiple disease drivers, these bispecific antibodies hold the promise of achieving higher efficacy and better disease control compared to traditional monoclonal antibodies.

The acquisition is particularly notable given the unmet medical need in the AD space. As mentioned, nearly 70% of patients do not achieve adequate disease control with standard-of-care treatments. The recent positive Phase 3 results for Eli Lilly's IL-13 targeted monoclonal antibody, Lebrikizumab, in a study focused on patients with darker skin tones further highlights the potential for better targeted therapies in this patient population.

Beyond the lead assets, the transaction will also provide Johnson & Johnson with access to Proteologix's broader bispecific antibody platform, which could be applied to various other diseases, further bolstering the company's capabilities in developing novel bispecific programs.

This acquisition is part of Johnson & Johnson's ongoing expansion strategy, which has seen the company make several major deals in both the pharmaceutical and medical device sectors over the past year. The $13.1 billion acquisition of Shockwave Medical, a vascular lithotripsy technology company, is one such example, which is expected to strengthen Johnson & Johnson's cardiovascular portfolio.

With these strategic moves, Johnson & Johnson is positioning itself as a leader in the immunology and medical technology spaces, continuously expanding its commercial footprint and pipeline to better serve patients with unmet medical needs. The Proteologix acquisition, in particular, showcases the company's commitment to advancing innovative bispecific antibody technologies to address complex immune-mediated diseases.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构